Neonatal uterus and vagina express estrogen receptor 1 (ESR1) and respond mitogenically to exogenous estrogens. However, neonatal ovariectomy does not inhibit preweaning uterine cell proliferation, indicating that this process is estrogen independent. Extensive literature suggests that ESR1 can be activated by growth factors in a ligand-independent manner and drive uterine cell proliferation. Alternatively, neonatal uterine cell proliferation could be ESR1 independent despite its obligatory role in adult luminal epithelial proliferation. To determine ESR1's role in uterine and vaginal development, we analyzed cell proliferation, apoptosis, and uterine gland development (adenogenesis) in wild-type (WT) and Esr1 knockout (Esr1KO) mice from Postnatal Day 2 to Postnatal Day 60. Uterine and vaginal cell proliferation, apoptosis, and uterine adenogenesis were comparable in WT and Esr1KO mice before weaning. By Days 29-60, glands had regressed, and uterine cell proliferation was reduced in Esr1KO mice in contrast to continued adenogenesis and proliferation in WT. Apoptosis in Esr1KO uterine epithelium was not increased compared to WT at any age, indicating that differences in cell proliferation, rather than apoptosis, cause divergence of uterine size in these two groups at puberty. Similarly, vaginal epithelial proliferation was reduced, and the epithelium became atrophic in Esr1KO mice by 29 days of age and later in Esr1KO mice. These results indicate that preweaning uterine and vaginal development is ESR1 independent but becomes dependent on ESR1 by Day 29 on. It is not yet clear what mechanisms drive preweaning vaginal and uterine development, but ligand-independent activation of ESR1 is not involved.
INTRODUCTION
The major mitogen for adult uterine luminal epithelium (LE) is 17b-estradiol (E2). In ovariectomized (E2 deficient) adult mice, uterine LE proliferation is minimal, but extensive proliferation is induced by E2 administration [1] . Similar increases are observed in intact mice during proestrous in response to high circulating E2 [1, 2] .
Uterine cell proliferation is high in neonatal mice despite low circulating E2 concentrations [3, 4] . Proliferation declines steadily with age, reaching a nadir at about Days 15-20, then increases as juvenile animals enter puberty, and circulating E2 increases [3] . Importantly, preweaning uterine epithelial and stromal proliferation and overall uterine growth are similar in both intact and ovariectomized/adrenalectomized mice, indicating that these processes are E2 independent in neonates [3] despite obligatory dependence on E2 in adults. Furthermore, neonatal mouse uteri continue to proliferate robustly following grafting into adult ovariectomized mice, again indicating the E2 independence of cell proliferation [5] .
If E2 is not needed for neonatal uterine cell proliferation, how is this process regulated? Extensive evidence has suggested that growth factors may induce ligand-independent activation of ESR1 [6] [7] [8] [9] [10] , and this could drive normal uterine growth following neonatal ovariectomy [11] [12] [13] . Conversely, neonatal uterine growth could be ESR1 independent despite its obligatory role in normal pubertal and adult uterine function [14, 15] .
Estrogen receptor 1 is expressed in the fetal Mullerian ducts before birth [16] , and immediately after birth in the neonatal mouse uterus, ESR1 is initially expressed only in the mesenchyme, but epithelial ESR1 expression begins around Day 4 [4, [16] [17] [18] . Expression of ESR1 is also seen in the neonatal vaginal mesenchyme/stroma and epithelium, which is in contrast to neonatal uterus [16, 17, 19] . Although neonatal uterine LE does not require E2 for proliferation, estrogens induce robust increases in neonatal uterine epithelial proliferation [3, 4, 20] through effects on mesenchymal/stromal ESR1 [21, 22] .
The Esr1 knockout (Esr1KO) mouse has been used extensively to delineate roles of ESR1 in reproductive and nonreproductive organs [14, 15] . In Esr1KO mice, initial reproductive tract differentiation occurs, but the adult mouse uterus and vagina are atrophic [14, 15] . The Esr1KO mouse provides a powerful tool to understand ESR1's role in uterine and vaginal cell proliferation and uterine adenogenesis during the neonatal/juvenile period. In this study, we used Esr1KO mice to determine whether neonatal/juvenile uterine and vaginal development requires ESR1. Our results show that ESR1 is not involved in or necessary for preweaning vaginal and uterine development. However, by Day 29 and later, a clear dependence on ESR1 for normal reproductive development occurs.
MATERIALS AND METHODS

Animals, Genotyping, and Animal Care
The Esr1KO mice were on a mixed C57BL/6 and 129SV background and were produced by ZP3-Cre-mediated excision of exon 3, generating a fully disrupted Esr1 mutant lacking all transcripts downstream of exon 2 [14] . These mice lack functional ESR1 and are phenotypically similar to Esr1KO mice originally developed in 1993 [15] . Females that were wild-type (WT) or homozygous or heterozygous for the Esr1 null mutation [14] were utilized in all experiments; the latter were a generous gift from Drs. Pierre Chambon and Andrée Krust. Due to infertility of both male and female Esr1KO mice, heterozygous males and females were bred to generate Esr1KO females.
Mice were housed in polycarbonate mice cages at 258C with 12L:12D cycles and given water and a standard rodent diet ad libitum. All experiments were approved by the University of Florida IACUC and conducted in accordance with the National Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals. Day of birth was considered Day 0. Uteri were removed from females in litters at 2, 6, 10, 14, 18, and 22 days of age; vaginas were also removed from mice at Postnatal Days 10, 14, and 22. Tissues were processed for histology and immunohistochemistry, and mice were genotyped retrospectively by genomic DNA isolated from tail tips [14] . Some uteri and vaginas from WT, heterozygote, and Esr1KO mice at 29, 35, and 60 days of age were also examined to assess cell proliferation and uterine adenogenesis postweaning.
Progesterone (P4) Effects in Esr1KO Uteri
Both neonatal and adult uterus show high expression of progesterone receptor (PR) in the epithelium and lower PR expression in the mesenchyme/ stroma [23, 24] . One dose of 40 lg of P4/g body weight (BW) administered neonatally maximally inhibits uterine epithelial proliferation 1 day later [5, 25] . To assess inhibition of uterine epithelial proliferation by P4, WT, heterozygote, and Esr1KO mice were given subcutaneously 40 lg/g BW of P4 (SigmaAldrich) in 0.05 ml of peanut oil at Postnatal Day 5; controls received peanut oil alone. Uteri were removed 24 h later and processed for immunohistochemistry.
Immunohistochemistry for MKI67 and FOXA2
To assess cell proliferation, slides were stained for the cell proliferation marker MKI67 using a rabbit monoclonal IgG to human MKI67 (catalog no. ab16667; Abcam Inc.). Tissues were immersion fixed in 10% neutral-buffered formalin, paraffin embedded, sectioned at 5-6 lm, and immunostained for MKI67 following antigen retrieval as described previously [26] . Negative controls were processed without primary antibody. Following immunostaining, tissues were counterstained with Gill hematoxylin (catalog no. 245-654; Fisher Scientific).
Uteri from WT, heterozygote, and Esr1KO mice were immunostained for forkhead box protein A2 (FOXA2), a specific marker for glandular epithelium [27, 28] , between birth and adulthood to unequivocally identify and allow quantitation of uterine glands in the various ages and genotypes. A rabbit monoclonal IgG to human FOXA2 (catalog no. LS-C138006; LifeSpan Biosciences) at a dilution of 1000:1 was used to stain uterine tissues fixed and sectioned as above. Negative controls were processed without primary antibody and counterstained as above.
TUNEL Assay
Apoptosis was detected in paraffin-embedded sections of WT and Esr1KO uteri using the TACS 2 TdT-DAB In Situ Apoptosis Detection kit (catalog no. 4810-30-K; Trevigen, Inc.), following the manufacturer's protocol. Briefly, after in situ terminal deoxynucleotidyl transferase (TdT) enzyme labeling with biotinylated nucleotide, streptavidin-horseradish peroxidase was applied, and apoptotic cells were visualized using DAB (3, 3 0 -diaminobenzidine) as the substrate and methyl green as a counterstain. From each WT and Esr1KO mouse uterus and vagina, at least three to four sections were stained and analyzed for apoptosis.
Statistical Analyses and Quantitation of Labeling Indices, Gland Number, and Apoptosis
Labeling index (proliferating MKI67-labeled cells/total cell counted) was determined by analyzing MKI67 immunostained images taken at 2503 magnification. All uterine and vaginal basal epithelial cells or at least .500 stromal cells in the region between the LE and the myometrium from randomly chosen areas in two tissue sections (obtained at ;100-lm intervals) per uterine horn were counted from WT, heterozygous, and Esr1KO mice. Apoptosis in WT and Esr1KO uterine and vaginal epithelium at 14, 29, and 35 days was determined in TUNEL-stained images (taken at 2503 magnification) by counting apoptotic epithelial cells per millimeter of basement membrane or square millimeter of epithelial area, respectively, using the NIH software program ImageJ. Vaginal epithelial thickness (in micrometers) was also determined using ImageJ. Gland number was determined by counting all uterine glands (as determined by FOXA2 staining) in four to six uterine cross sections from each animal. All data presented in a particular figure were scored blind by the same observer. Data from two groups at various ages were analyzed using the unpaired t-test. Whenever three groups were compared, one-way analysis of variance (ANOVA) followed by the Tukey multiple comparison test was used. Data from P4-treated WT, heterozygous, and Esr1KO mice were analyzed by two-way ANOVA followed by the Sidak multiple comparison test. Data are presented as mean 6 SEM. Differences were considered significant at P , 0.05. Statistical analysis was carried out using Graph Pad Prism 6.0 (Graph Pad Software, Inc.).
RESULTS
Uterine Development in WT, Heterozygote, and Esr1KO Mice
Proliferation of uterine LE and stromal cells were initially high after birth (Day 2) in WT, heterozygote, and Esr1KO mice and diminished with age, reaching a minimum at weaning
, and glandular epithelium (C) of WT, heterozygote (Het), and Esr1KO uteri from Postnatal Day 2 to Postnatal Day 22, measured by MKI67 staining. Overall luminal and glandular epithelial and stromal proliferation decreased with age in all groups, although patterns of proliferation varied among the different cell types. There were no statistically significant differences in proliferation of any of these cell types among the three groups at any age examined, indicating that uterine cell proliferation is comparable in WT, heterozygote, and Esr1KO mice from birth to weaning; n 3 for all genotypes and ages.
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(Day 22; Figs. 1, A and B, and 2), as documented previously [3] . Critically, both epithelial (Figs. 1A and 2) and stromal (Figs. 1B and 2) proliferation was comparable in all groups up to Day 22.
Uterine gland development began at approximately Postnatal Day 6 ( Fig. 2 ) in all genotypes, as LE buds invaded the underlying mesenchyme. Glandular epithelial proliferation was comparable in WT, heterozygote, and Esr1KO mice up to Day 22 ( Figs. 1C and 2 ). For all genotypes, LE proliferation decreased sharply from high neonatal levels by Day 10, while in glandular epithelium, high proliferation persisted through Day 14. Morphologically, glands became progressively more extensive in both size and number from the initiation of adenogenesis at Day 6 through Day 22 in all genotypes (Fig.  2) .
By Day 29, there was a 27% reduction in uterine epithelial proliferation in Esr1KO mice (45.3 6 3.6%; n ¼ 5) compared to WT mice (61.9 6 9.8%; n ¼ 5), although this did not reach statistical significance (P . 0.05) due to variability in WT mice resulting from initiation of cyclicity. Similarly, at Day 35, uterine epithelial proliferation in Esr1KO mice was reduced 51% compared to WT mice (17.3 6 1.7% and 35.6 6 24.5%, respectively; n ¼ 3 for both genotypes), but again this was not statistically significant (P . 0.05) because cycling WT mice at this age show dramatically different uterine epithelial proliferation, depending on their estrous cycle phase. Notably, significant epithelial proliferation persisted at these ages in Esr1KO uterine epithelium in contrast to Day 60, when it is minimal (Supplemental Figure S1 ; Supplemental Data are available online at www.biolreprod.org).
Consistent with glandular epithelial proliferation, gland numbers in WT, heterozygote, and Esr1KO uteri were similar at Days 14 and 22 (Figs. 1C, 2, and 3A) when quantitated using FOXA2 immunostaining [27] . In contrast, uterine gland numbers in WT and heterozygote mice were significantly greater than in Esr1KO uteri at Days 29 and 35 in Esr1KO mice (Fig. 3, A and B) , with minimal uterine glands in Esr1KO uteri observed by Day 60. Thus, neonatal adenogenesis is independent of E2/ESR1 signaling, but beginning at puberty, both further gland formation and maintenance of existing uterine glands require E2/ESR1 signaling.
Overall uterine size and morphology were comparable in all genotypes until Day 22 (not shown). However, divergence between Esr1KO and WT/heterozygote uterine development became apparent around puberty, as reflected in reproductive tract whole mounts (Fig. 4) . Uterine thickness in Esr1KO mice is modestly diminished by Day 29 and clearly diminished by 
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Day 35 (Fig. 4) . By Day 60, Esr1KO uteri are atrophic relative to WT and heterozygotes, characteristic of adult Esr1KO mice.
Uterine Epithelial Apoptosis in WT and Esr1KO Mice
Luminal epithelial apoptosis was comparable in WT and Esr1KO uteri at Days 14 and 29 (Fig. 5) . Luminal epithelial apoptosis in Esr1KO uteri remained low at Day 35 in contrast to WT uteri, where there was a trend toward an increase compared to the Esr1KO uteri (P ¼ 0.066) as a result of the onset of cyclicity. Glandular epithelial apoptosis in Esr1KO uteri at Days 14, 29, and 35 was not increased compared to WT (data not shown).
Effects of P4 on Cell Proliferation in WT, Heterozygote, and Esr1KO Mice
The robust uterine epithelial proliferation at Day 6 in vehicle-treated WT, heterozygote, and Esr1KO pups (Fig. 6 , A and C) was strongly and equally suppressed by P4 (40 lg/g BW) in all genotypes (Fig. 6, A and C) . Conversely, stromal proliferation was stimulated by P4 in all genotypes (Fig. 6 , B and C). Thus, inhibitory effects of P4 on neonatal uterine epithelial proliferation do not involve ESR1.
Vaginal Development in WT, Heterozygote, and Esr1KO Mice
Vaginal basal epithelial proliferation (Fig. 7B ) was similar at Days 10 and 22 in all genotypes but significantly (P , 0.05) reduced in Esr1KO compared to WT and heterozygote mice by Days 29 and 35 (Fig. 7, A and B) . Vaginal epithelial thickness was also reduced in Esr1KO mice at Days 29 and 35 (Fig. 7C) . The stratified squamous epithelial morphology and cornification observed at Days 29 and 35 in WT and heterozygote mice was not seen in Esr1KO mice (Fig. 7 , A and C) due in part to increased apoptotic activity in the vaginal epithelium of the Esr1KO mice (Fig. 7D) . Apoptosis in the Day 35 WT vaginal epithelium was basically confined to the apical layers of the stratified vaginal epithelium. In contrast, more extensive FIG. 3. Postnatal uterine adenogenesis in WT, heterozygote (Het), and Esr1KO. Uteri from WT, Het, and Esr1KO mice at various postnatal ages were immunostained for FOXA2, a marker for uterine glands, and the number of FOXA2-positive uterine glands was counted per uterine cross section. Neonatally, WT, Het, and Esr1KO mice showed normal adenogenesis, with similar numbers of FOXA2-positive uterine glands per cross section until Day 22 (A). However, gland number by Days 29 and 35 was lower in Esr1KO mice than in WT or Het (A, B), and by Day 60, uterine glands were nearly absent. All images are the same magnification; bar ¼ 100 lm; n ¼ 3-4 for all genotypes at Days 14 and 22, n ¼ 4-6 for all genotypes at Day 29, n ¼ 3 for all genotypes at Day 35, and n ¼ 1 for all genotypes at Day 60. **P , 0.01; *P , 0.05.
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Esr1KO mouse, with apoptotic cells occurring throughout the suprabasal epithelium; this may account for altered vaginal epithelial morphology in Esr1KO mice by this age. The changes in cell proliferation and apoptosis result in reduced vaginal size in Esr1KO compared to WT mice by Day 35 and especially by Day 60 (Fig. 4) .
DISCUSSION
Growth and cell proliferation in preweaning rodent uteri do not require E2 [3] , the major mitogen for adult uteri. This study analyzed uterine and vaginal development in Esr1KO mice to determine whether this process involved ligand-independent activation of ESR1 or was ESR1 independent. Our results indicate that preweaning uterine and vaginal cell proliferation are comparable to WT, heterozygote, and Esr1KO mice and thus ESR1 independent despite mitogenic responsiveness of WT uteri to estrogens during neonatal and immature (Day 21) stages [3, 4, 20] . However, by Days 29 and 35, Esr1KO uterus and vagina began to show atrophic changes compared to WT mice, at least in part due to reduced cell proliferation in these organs in Esr1KO mice. By Day 35, vaginal and uterine cell proliferation is still significant in Esr1KO mice in contrast to minimal levels at Day 60. Thus, acquisition of dependence on E2/ESR1 signaling is a gradual process commencing at puberty but not reaching totality for some time.
In mice, uterine adenogenesis begins at Neonatal Day 6 [25] , and maximal gland number and size is reached by 60 days [29] . In adult Esr1KO mice, only rudimentary glands are seen [14, 15] . Stewart et al. [29] reported that glands were present in Esr1KO mice at 10 days of age, indicating that initial adenogenesis occurs without ESR1.
In the mouse uterus, FOXA2 (hepatocyte nuclear factors 3b) is expressed exclusively in glandular epithelium [27] . Thus, in the present study, we compared adenogenesis in WT and Esr1KO mice using FOXA2 immunostaining [27, 30] . Adenogenesis was comparable in WT and Esr1KO mice up to Day 22, indicating that prepubertal adenogenesis is ESR1 independent. In contrast, by Days 29 and 35, gland numbers in Esr1KO mice were decreased compared to WT and heterozygote mice, reflecting gland regression beginning by Day 29 and later in Esr1KO mice that culminates in the adult aglandular 
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Esr1KO phenotype by Day 60 [14, 15] . This does not appear to result from increased apoptosis.
Mice lacking uterine FOXA2 do not have uterine glands in adulthood, suggesting that FOXA2 is important for adenogenesis [27] . Recently, FOXA2 has been shown to regulate pathways associated with WNT signaling, the cell cycle, and other processes and also has repressive effects on various cell signaling pathways [28] . The normal FOXA2 expression during adenogenesis and gland regression in Esr1KO mice indicate that FOXA2 is not dependent on E2/ESR1. The continued high FOXA2 expression in regressing glands in Esr1KO mice at Days 29 and 35 suggests that FOXA2 expression is not sufficient to prevent regression during this time. Interestingly, in leucine-rich repeat-containing G-proteincoupled receptor 4 (Lgr4) knockout mice, uterine glands were present at 3 wk of age, although their number was reduced compared to WT mice, but by 9 wk, glands were completely absent [31] . Common pathways in both Esr1KO and Lgr4KO mice might contribute to adult loss of glands following prepubertal adenogenesis.
Overall uterine and vaginal growth reflects a balance between cell proliferation and apoptosis. Thus, despite comparable proliferation in these tissues in WT and Esr1KO mice, it was also important to determine if the lack of ESR1 increased apoptosis during preweaning or pubertal development since estrogens have both proliferative and antiapoptotic effects on adult uterine epithelium [22, 32] . Uterine epithelial apoptosis in Esr1KO mice was not greater than WT, indicating that lack of ESR1 does not increase preweaning (Day 14) or pubertal (Day 29) uterine epithelial apoptosis. This suggests that the atrophic morphology of adult Esr1KO uteri is a result of lack of cell proliferation and growth after puberty and not due to increased apoptosis. Although epithelial cell apoptosis in Day 14 WT and Esr1KO vaginas was similar, there was an increase in apoptosis of suprabasal epithelium in the vagina at Days 29 and 35 in Esr1KO mice that, along with lower epithelial proliferation, may contribute to the reduced epithelial height-altered vaginal epithelial morphology seen at Day 29 and later compared to WT. A, B) . There were no significant differences between WT and Esr1KO groups at any age, although there was a strong trend toward an increase in the WT compared to the Esr1KO at Day 35 (P ¼ 0.0661). All images are the same magnification; bar ¼ 50 lm. Inset images showing apoptotic cells on Day 14 were taken using oil immersion; n ¼ 3-5 for all genotypes and ages.
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Literature extending over two decades indicates that growth factors can mimic E2-induced uterine epithelial proliferation and growth [6] [7] [8] [9] [10] [33] [34] [35] . For example, treatment of ovariectomized adult WT mice with either epidermal growth factor (EGF) or E2 produced similar increases in uterine and vaginal epithelial proliferation [6] . This did not occur in ovariectomized Esr1KO mice [7] despite the presence of functional EGF receptors in the uterus and other organs, indicating that EGF-induced uterine and vaginal epithelial proliferation is mediated through ESR1. Similarly, insulin-like growth factor 1 (IGF-1) produced increases in uterine epithelial proliferation closely mimicking those seen with E2 in ovariectomized WT but not Esr1KO mice despite functional IGF-1 receptors in uteri of these animals [8] .
Both EGF and IGF-1 can activate mitogen-activated protein kinase to induce ligand-independent activation of ESR1 through phosphorylation and subsequent downstream events mimicking those seen with E2 [8, 9, 34, 36] . In addition to EGF and IGF-1, transforming growth factor alpha and even leptin can transcriptionally activate ESR1 [10, 37] .
Various growth factors and their receptors are expressed in developing uterus and vagina, consistent with a role in neonatal growth through ligand-independent activation of ESR1 when cell proliferation is not obligatorily dependent on E2. For example, keratinocyte growth factor (KGF) and its receptors are expressed in neonatal uterus and vagina, and KGF stimulated vaginal and uterine epithelial proliferation in neonatal mice [38, 39] .
Fibroblast growth factors, hepatocyte growth factor, EGF, IGF-1, and their receptors are all also present at high levels in neonatal uterus and vagina of mice and sheep [12, 30, [40] [41] [42] [43] . Neonatal and immature uteri respond at nearly equal sensitivity to EGF, which produces both growth and stromal and epithelial proliferation [35] . Ogasawara et al. [3] initially suggested that neonatal uterine growth might be autonomous. However, subsequent literature [6-10, 12, 33, 35] indicates that growth factors and their receptors are expressed neonatally in uterus FIG. 6 . Neonatal P4 similarly inhibits uterine epithelial proliferation in WT, heterozygote (Het), and Esr1KO mice. A) Luminal epithelial (LE) proliferation. Treatment with P4 produced highly significant (P , 0.0001) and comparable decreases in epithelial proliferation among all genotypes. B) Stromal (S) proliferation. The stimulatory effect of P4 on stromal proliferation was modest but significant and similar in all groups. C) Immunohistochemical staining for MKI67 to visualize cell proliferation. Note the comparable P4 effects in LE of all genotypes compared to their vehicle-treated controls. In contrast to inhibitory effects on LE proliferation, P4 stimulated stromal proliferation in all groups; n ¼ 3 for all vehicle-treated samples, and n ¼ 4 for all P4-treated samples. All images are the same magnification; bar ¼ 100 lm. **P , 0.01; ***P , 0.001; ****P , 0.0001.
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and vagina and that neonatal and adult reproductive tracts show similar mitogenic responses to these growth factors. This led to the hypothesis that growth factor signaling could regulate neonatal uterine and vaginal epithelial proliferation through ligand-independent activation of ESR1, as suggested by research with both rodents and large domestic animals, such as sheep and pigs [11, 12, 44, 45] . Neonatal porcine uterus expresses ESR1, but neonatal ovariectomy does not affect uterine development [13] , similar to mice [3] . However, the antiestrogen ICI 182 780 inhibited uterine development [11] , suggesting that ESR1 is needed for neonatal uterine growth and that ligand-independent activation of ESR1 could be required for normal uterine development in this species in contrast to the mouse.
Relaxin is present in high quantities in milk of sows and other species in the early neonatal period [46] . Relaxin induces uterotrophic effects in neonatal porcine and immature rat uterus, but the antiestrogen ICI 182 780 blocked relaxin's uterotrophic effects in both neonatal pigs and rats [44, 45] . This suggests that relaxin induced activation and signaling through ESR1 and may act by ligand-independent activation of ESR1 in neonatal uterus in many or all species.
Our results demonstrate that ligand-independent activation of ESR1 is not involved in preweaning uterine or vaginal development in mice. Thus, neonatal effects of growth factors must occur through mechanisms other than activating ESR1. Our study does not identify how neonatal uterine and vaginal cell proliferation and uterine adenogenesis are controlled. However, by definitively establishing that the mechanism that seemed likely to regulate this process, ligand-independent activation of ESR1, is not involved, current results should facilitate future studies to understand mechanisms regulating preweaning development of these organs. and altered epithelial morphology at these postnatal ages (A). All images are the same magnification; bar ¼ 100 lm; n ¼ 3-6 for all genotypes and ages. *P , 0.05 versus WT; **P , 0.01 versus WT; ***P , 0.001 versus WT. In D at Day 29, P ¼ 0.0594 for WT versus Esr1KO.
NANJAPPA ET AL.
Our results showing that P4 normally inhibited uterine epithelial proliferation in Esr1KO mice lacking ESR1 suggests that this P4 effect is independent of ESR1 and not acting on a process or processes associated with ESR1. These results are consistent with reports that other uterine P4 effects (e.g., decidual response) occur in Esr1KO mice [47, 48] . In ovariectomized adult mice, P4 modestly increases uterine stromal cell proliferation, while P4 þ E2 treatment induces greater proliferation [1] . In contrast, P4 alone induces large increases in stromal proliferation in neonatal uteri [5] . Stromal cell stimulation by P4 in neonatal mice, where E2 concentrations are low, suggests that this process is independent of E2/ ESR1, which is consistent with our results showing that P4-induced neonatal uterine stromal proliferation was equal in all groups.
In conclusion, normal preweaning uterine and vaginal development occurs in the absence of ESR1 and then becomes dependent on E2/ESR1 at puberty. Furthermore, ESR1 is not involved in P4 inhibition of neonatal uterine epithelial proliferation. Mechanisms regulating neonatal uterine and vaginal cell proliferation remain unclear, but our results unequivocally indicate that ligand-independent activation of ESR1, previously suggested as a potential mechanism, is not involved in mice.
